Your browser doesn't support javascript.
loading
Percolation and binding of MAB BW 494 to pancreatic carcinoma tissues during high dose immunotherapy and consequences for future therapy modalities.
Bosslet, K; Keweloh, H C; Hermentin, P; Muhrer, K H; Sedlacek, H H; Schulz, G.
Afiliación
  • Bosslet K; Research Laboratories of Behringwerke AG, Marburg, Germany.
Behring Inst Mitt ; (87): 68-75, 1990 Dec.
Article en En | MEDLINE | ID: mdl-2096821
ABSTRACT
The distribution of the monoclonal antibody (MAb) BW494 in human pancreatic carcinoma biopsies during high dose i.v. immunotherapy was investigated. Using immunohistochemical techniques combined with anti-idiotypic, endothelial cell specific and bispecific MAbs it was shown that 3 days after onset of immunotherapy, MAb BW494 was bivalently bound to tumor cells in some highly vascualized areas near capillaries. No binding was observed in other highly vascularized tumor cell areas although the epitope detected by MAb BW494 was present. In contrast to our expectation the majority of the tumor cells was not yet saturated by the antibody, probably due to diffusion barriers in the solid tumor tissue.
Asunto(s)
Buscar en Google
Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Inmunoterapia / Anticuerpos Monoclonales Idioma: En Revista: Behring Inst Mitt Año: 1990 Tipo del documento: Article
Buscar en Google
Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Inmunoterapia / Anticuerpos Monoclonales Idioma: En Revista: Behring Inst Mitt Año: 1990 Tipo del documento: Article